<DOC>
	<DOCNO>NCT00445692</DOCNO>
	<brief_summary>This phase II trial study lenalidomide , dexamethasone , clarithromycin treat patient undergone stem cell transplant multiple myeloma . Biological therapy , lenalidomide clarithromycin , may stimulate immune system different way stop cancer cell grow . Drugs use chemotherapy , dexamethasone , work different way stop growth cancer cell , either kill cell stop divide . Giving lenalidomide together dexamethasone clarithromycin may effective treatment multiple myeloma .</brief_summary>
	<brief_title>Lenalidomide , Dexamethasone , Clarithromycin Treating Patients Who Have Undergone Stem Cell Transplant Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Evaluate toxicity use lenalidomide/biaxin ( clarithromycin ) /dexamethasone maintenance therapy autologous/syngeneic transplant . II . Evaluate median time disease progression . III . Evaluate survival . OUTLINE : Patients receive clarithromycin orally ( PO ) twice daily ( BID ) dexamethasone PO week . Treatment clarithromycin dexamethasone continue 1 year absence disease progression unacceptable toxicity . Patients also receive lenalidomide PO daily ( QD ) day 1-14 . Courses lenalidomide repeat every 21 day absence disease progression unacceptable toxicity . NOTE : *After one year treatment , dexamethasone taper additional 4 week . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Any autologous syngeneic patient underwent high dose melphalan ( &gt; = 140 mg/m^2 ) therapy/peripheral blood stem cell ( PBSC ) bone marrow ( BM ) rescue stage multiple myeloma participate another clinical transplant trial also evaluate longterm disease free survival survival Platelet count ( transfusion independent ) &gt; 50,000 cells/mm^3 absolute granulocyte count &gt; 1500 cells/mm^3 5 calendar day recovery high dose therapy Patients 30 day 120 day transplant Willingness ability comply Food Drug Administration ( FDA ) mandate REV ASSIST Program , Celgene System Lenalidomide Education Prescribing Safety Signing write informed consent form Karnofsky score less 70 A leave ventricular ejection fraction le 45 % immediately pre transplant ; patient congestive heart disease transplant , history myocardial infarction ( MI ) , history coronary artery disease Total bilirubin great 2 mg/ml ( unless history Gilbert 's disease ) , serum glutamicoxaloacetic transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) &gt; 2.5 x upper limit normal Calculated CockcroftGault formula measure serum creatinine clearance &lt; 25 ml/minute Pregnant and/or lactate female Patients give informed consent Patients untreated systemic infection Patients history prior transplant treatment combination therapy Lenalidomide/Biaxin steroid without response Patients allergic lenalidomide , biaxin dexamethasone Referring physician register REV ASSIST program unwilling oversee care patient study comply FDAmandated REV ASSIST Program Patients unwilling practice adequate form contraception clinically indicate 30 day stop therapy ; male patient study need consult use latex condom ( even vasectomy ) every time sex woman able child treat 30 day stop drug Patients &gt; = grade 3 peripheral neuropathy Prior history uncontrollable side effect dexamethasone therapy A prior history human immunodeficiency virus ( HIV ) positivity pretransplant evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>